HC Wainwright Analysts Raise Earnings Estimates for Indivior

Indivior PLC (NASDAQ:INDV) – Investment analysts at HC Wainwright boosted their Q3 2026 EPS estimates for shares of Indivior in a research note issued on Tuesday, August 4th. HC Wainwright analyst B. Folkes now forecasts that the company will earn $0.93 per share for the quarter, up from their prior forecast of $0.78. HC Wainwright also issued estimates for Indivior’s Q4 2026 earnings at $1.07 EPS, FY2026 earnings at $3.66 EPS, FY2027 earnings at $3.83 EPS, FY2028 earnings at $3.99 EPS, FY2029 earnings at $4.22 EPS and FY2030 earnings at $4.46 EPS.

Indivior (NASDAQ:INDV) last posted its quarterly earnings data on Tuesday, June 30th. The company reported $5.75 earnings per share (EPS) for the quarter. The company had revenue of $343.00 million for the quarter. Indivior had a net margin of 26.65% and a negative return on equity of 283.11%.

INDV has been the subject of several other research reports. Craig Hallum reaffirmed a “buy” rating and issued a $53.00 price target on shares of Indivior in a report on Tuesday. Zacks Research cut Indivior from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 29th. Barclays lowered their price objective on Indivior from $46.00 to $43.00 and set an “overweight” rating on the stock in a research report on Wednesday. Finally, Weiss Ratings raised Indivior from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, July 24th. Five analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $45.17.

Indivior Stock Up 6.1%

INDV stock opened at $38.73 on Thursday. Indivior has a twelve month low of $21.48 and a twelve month high of $42.81. The company has a market cap of $4.57 billion, a PE ratio of 13.88 and a beta of 0.86. The business’s 50-day simple moving average is $39.18 and its 200 day simple moving average is $35.57.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Handelsbanken Fonder AB acquired a new stake in shares of Indivior in the 2nd quarter valued at $1,859,000. Hennion & Walsh Asset Management Inc. acquired a new position in shares of Indivior during the second quarter valued at $14,781,000. MRA Advisory Group bought a new position in Indivior in the second quarter valued at about $434,000. Assenagon Asset Management S.A. bought a new position in Indivior in the second quarter valued at about $63,224,000. Finally, GAMMA Investing LLC bought a new position in Indivior in the second quarter valued at about $66,000. Institutional investors own 60.33% of the company’s stock.

Insider Buying and Selling at Indivior

In other Indivior news, CFO Ryan Preblick sold 36,000 shares of the company’s stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $37.70, for a total transaction of $1,357,200.00. Following the sale, the chief financial officer directly owned 284,751 shares of the company’s stock, valued at approximately $10,735,112.70. This represents a 11.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Christian Heidbreder sold 18,586 shares of the stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $41.14, for a total value of $764,628.04. Following the sale, the insider owned 209,337 shares in the company, valued at approximately $8,612,124.18. This trade represents a 8.15% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.74% of the company’s stock.

Indivior News Roundup

Here are the key news stories impacting Indivior this week:

• Positive Sentiment: Analyst estimates raised materially: HC Wainwright increased its EPS forecasts for every reported period, including FY2026 to $3.66 from $3.08, FY2027 to $3.83 from $3.34, FY2028 to $3.99 from $3.48, FY2029 to $4.22 from $3.70 and FY2030 to $4.46 from $3.93. Its Q3 and Q4 2026 estimates also rose to $0.93 and $1.07, respectively, signaling stronger anticipated earnings momentum.
• Positive Sentiment: Merger and operating performance support the outlook: Indivior announced plans to merge with Supernus Pharmaceuticals to create a CNS-focused biopharmaceutical company. The company also reportedly exceeded second-quarter earnings and revenue expectations and raised its 2026 outlook. Indivior merger, earnings and outlook article
• Positive Sentiment: Insider purchase: Chief Accounting Officer Woodrow Anderson bought 1,500 shares for approximately $54,420, increasing his direct holdings by 6.09%. The purchase may be viewed as a modest vote of confidence in Indivior’s valuation and prospects. Indivior insider purchase article
• Neutral Sentiment: Analyst sentiment remains favorable overall, with five Buy ratings and two Holds and a consensus “Moderate Buy” recommendation. However, Barclays lowered its price target to $43 while maintaining an Overweight rating; the consensus target is $45.17. Indivior analyst recommendation article

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.